Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy
A Phase II Study to Evaluate the Efficacy of Regorafenib in C-kit Mutated Metastatic Malignant Melanoma Failed First-Line Dacarbazine, Temozolomide or Immune Therapy
Sponsor: Yonsei University
A PHASE2 clinical study on Melanoma, this trial is ongoing. The trial is conducted by Yonsei University and has accumulated 10 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
May 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
May 2021 — May 2023 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jul 2018 — Feb 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Yonsei University
For direct contact, visit the study record on ClinicalTrials.gov .